DaVita HealthCare (DVA) ended the recent trading session at $149.98, demonstrating a +1.19% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.25%.

DaVita (NYSE:DVA) is responding to declines in dialysis patient volumes by adjusting its clinical and business priorities. The company is focusing on higher vaccination rates and newer therapies as ...

DVA is gaining attention after strong Q4 results and steady global expansion, though its heavy reliance on commercial insurers remains a concern.

DAVID MICHAEL STAFFIERI, Chief Operating Officer at DaVita (NYSE:DVA), executed a substantial insider sell on August 19, according to an SEC filing. What Happened: STAFFIERI's decision to sell 42,119 ...

DaVita Inc.'s stock was tumbling 13.5% Friday to lead S&P 500 decliners, after Warren Buffett's Berkshire Hathaway Inc. pared its stake in the provider of kidney dialysis. DaVita's stock (DVA) was on ...

Please provide your email address to receive an email when new articles are posted on . The price of DaVita stock plunged last week after the company reported a major drop in revenue in the third ...

Detailed price information for Davita Healthcare Partners Inc (DVA-N) from The Globe and Mail including charting and trades.

DaVita (NYSE:DVA) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release. Analysts are estimating that DaVita ...

Chronic kidney disease is one of the most prevalent, and deadly, issues plaguing the health of the US: according to the CDC, there are about 37 million US adults who are estimated to have chronic ...

Shares of DaVita Inc. plummeted in active trading Friday, to suffer their worst performance in more than two decades, after the dialysis company reported third-quarter that fell well below ...

Medtronic and DaVita Inc. are teaming up to create a new, independent company focused on kidney care. The new company will be owned equally by the two and led by an independent management team.

DaVita is a stock that has been in Warren Buffett's portfolio for many years. Now the company is under short-term pressure from higher patient costs, labor issues, higher interest expenses, and lower ...